DEMADEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Demadex, and when can generic versions of Demadex launch?
Demadex is a drug marketed by Roche and Mylan Speciality Lp and is included in two NDAs.
The generic ingredient in DEMADEX is torsemide. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the torsemide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Demadex
A generic version of DEMADEX was approved as torsemide by STRIDES PHARMA on May 27th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DEMADEX?
- What are the global sales for DEMADEX?
- What is Average Wholesale Price for DEMADEX?
Summary for DEMADEX
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 126 |
| Clinical Trials: | 7 |
| Patent Applications: | 4,694 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DEMADEX |
| What excipients (inactive ingredients) are in DEMADEX? | DEMADEX excipients list |
| DailyMed Link: | DEMADEX at DailyMed |
Recent Clinical Trials for DEMADEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| New York City Health and Hospitals Corporation | Phase 4 |
| Sarfez Pharmaceuticals, Inc. | Phase 1 |
| Roxane Laboratories | N/A |
US Patents and Regulatory Information for DEMADEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roche | DEMADEX | torsemide | SOLUTION;INTRAVENOUS | 020137-002 | Aug 23, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-002 | Aug 23, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Roche | DEMADEX | torsemide | SOLUTION;INTRAVENOUS | 020137-001 | Aug 23, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-001 | Aug 23, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-004 | Aug 23, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-003 | Aug 23, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DEMADEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-002 | Aug 23, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-004 | Aug 23, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Roche | DEMADEX | torsemide | SOLUTION;INTRAVENOUS | 020137-002 | Aug 23, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-001 | Aug 23, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-003 | Aug 23, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-004 | Aug 23, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Roche | DEMADEX | torsemide | SOLUTION;INTRAVENOUS | 020137-002 | Aug 23, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DEMADEX
See the table below for patents covering DEMADEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 573454 | ⤷ Sign Up | |
| Argentina | 208769 | UN PROCEDIMIENTO PARA PREPARAR NUEVOS DERIVADOS DE LA 3-SULFONAMIDO-PIRIDINA | ⤷ Sign Up |
| Japan | S50142571 | ⤷ Sign Up | |
| Hungary | T42069 | ⤷ Sign Up | |
| Denmark | 174624 | ⤷ Sign Up | |
| Finland | 87993 | ⤷ Sign Up | |
| Australia | 578562 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
